Chronic pain is pain that lasts beyond 3 months. Chronic non-cancer pain conditions include osteoarthritis, low back pain, musculoskeletal pain, […]
CADTH recommends that Livmarli should be reimbursed by public drug plans for the treatment of cholestatic pruritus in patients with
CADTH recommends that public drug plans reimburse Hemgenix for the treatment of hemophilia B if certain conditions are met.
We recommend that Myalepta should be reimbursed by public drug plans as an adjunct to diet as a replacement therapy
CADTH recommends that Remsima SC be reimbursed by public drug plans as maintenance treatment for adults with moderately to severely
Post Content
CADTH recommends that Epidiolex be reimbursed by public drug plans for the adjunctive therapy of seizures associated with Dravet syndrome
CADTH recommends that Leqvio not be reimbursed by public drug plans as an adjunct to lifestyle changes, including diet, to
CADTH recommends that Adtralza should not be reimbursed by public drug plans for the treatment of moderate to severe atopic
Health care providers rely on laboratory tests to differentiate between respiratory illnesses that manifest in similar symptoms, such as COVID-19
Registration No: 771800548 Contact Number : +91-8249516996
